ATG-106 / Antengene, K2 Therapeutics - LARVOL DELTA

Antengene announces exclusive license agreement with MPM bioImpact-established K2 therapeutics for ATG-106 and option for undisclosed bispecific TCE (PRNewswire) - "K2 Therapeutics, established by MPM BioImpact, obtains exclusive global rights to develop and commercialize ATG-106 outside Greater China Antengene receives upfront and near-term considerations of approximately USD 20 million for ATG-106; eligible to receive up to USD 960.5 million in future milestones K2 Therapeutics enters into option agreement with Antengene to obtain exclusive global rights to develop and commercialize an undisclosed preclinical bispecific TCE candidate outside Greater China"

Licensing / partnership • Ovarian Cancer • Solid Tumor

ATG-106, a novel "2+1"format CDH6-targeted T-cell Engager (TCE), shows potent T cell dependent cytotoxicity and in vivo anti-tumor efficacy (AACR 2026) - "ATG-106 also induced tumor shrinkage and complete remission in OVCAR-3 model. ATG-106-RM was well tolerated in rhesus monkey at doses up to 10mg/kg.ConclusionsATG-106 demonstrated powerful T cell dependent cytotoxicity and in vivo anti-tumor efficacy against ovarian and renal cancer preclinically, which warrants further clinical evaluation."

Preclinical • Genito-urinary Cancer • Kidney Cancer • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Solid Tumor • CDH6

Business Updates: AnTenGager TCE Platform (PRNewswire) - "The Company plans to submit an IND application for ATG-106 in the second quarter of 2027.... The Company plans to submit an IND application for ATG-112 in the second quarter of 2027....Antengene plans to submit an IND application for ATG-110 (LY6G6D × CD3 TCE) in the first half of 2027 for the treatment of microsatellite-stable colorectal cancer."

IND • Bladder Cancer • Colorectal Cancer • Non Small Cell Lung Cancer • Ovarian Cancer • Renal Cell Carcinoma

Title: ATG-106, a novel ’2+1’ format CDH6-targeted T-cell Engager (TCE), shows potent T cell dependent cytotoxicity and in vivo anti-tumor efficacy (PRNewswire) - "Antengene to Present on...Preclinical Programs at AACR 2026....ATG-106 demonstrated reduced binding affinity to CD3-positive cells prior to CDH6 engagement while inducing significantly enhanced cytotoxic activity against CDH6-positive tumor cells compared with conventional TCE formats. In PBMC-humanized xenograft models of renal and ovarian cancer, ATG-106 induced robust tumor regression with complete responses observed in multiple treatment groups."

Preclinical • Kidney Cancer • Ovarian Cancer • Renal Cell Carcinoma

ATG-106 (CDH6 x CD3 TCE) (PRNewswire) - "A global first-in-class CDH6 x CD3 targeted TCE being developed for the treatment of ovarian cancer and kidney cancer. The Company plans to submit an IND for ATG-106 in the first half of 2027."

IND • Kidney Cancer • Ovarian Cancer

Antengene Hosts 2025 R&D Day Showcasing Encouraging Clinical Data and Solid Progress with Investigational Programs (The Malaysian Reserve) - "...it will present the latest data and future plans for three mid/late-stage clinical programs, including ATG-022 (CLDN18.2 antibody-drug conjugate [ADC]), ATG-037 (oral CD73 small molecule inhibitor), and ATG-101 (PD-L1/4-1BB bispecific antibody). The company will also share the latest progress on ATG-125 (B7H3 x PD-L1 bispecific ADC): A B7H3 x PD-L1 targeted therapy featuring “'O + ADC' dual-effect molecules for the treatment of solid tumors and its AnTenGager™ T-cell engager (TCE) technology platform which incorporates steric hindrance masking, along with updates on several key preclinical programs."

Clinical data • Colorectal Cancer • Hematological Malignancies • Melanoma • Neuroendocrine Carcinoma • Non Small Cell Lung Cancer • Ovarian Cancer

ATG-106, a novel '2+1' format CDH6-targeted T-cell engager (TCE), shows potent T cell dependent cytotoxicity and in vivo anti-tumor efficacy (SITC 2024) - "0.1 mg/kg, 0.3 mg/kg, and 1 mg/kg ATG-106 produced significant anti-tumor efficacy with mean TGI values of 132.53%, 140.34%, and 140.23%, respectively. Complete tumor remission was observed in 0.3 mg/kg (3 out of 6 mice) and 1 mg/kg (3 out of 6 mice) treatment groups"

Preclinical • Endocrine Cancer • Genito-urinary Cancer • Hematological Malignancies • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Solid Tumor • Thyroid Gland Carcinoma • CDH2 • CDH6

Title: ATG-106, a novel "2+1" format CDH6-targeted T-cell Engager (TCE), shows potent T cell dependent cytotoxicity and in vivo anti-tumor efficacy (PRNewswire) - "Antengene Corporation Limited...announced that it will present results from...programs at the 2024 Society for Immunotherapy of Cancer Annual Meeting (SITC 2024)....Abstract Number: 1069:....ATG-106, a '2+1' CDH6 x CD3 TCE, was designed to address CRS challenge by targeting CDH6 and activating T cells only in the presence of CDH6-positive cells, minimizing CRS risk. Preclinical studies showed strong binding affinity to CDH6+ cells and potent T-cell-dependent cytotoxicity. It induced lower cytokine release in vitro compared to benchmarks. In vivo studies using ovarian cancer xenograft models demonstrated that ATG-106 achieved significant tumor growth inhibition (TGI) with tumor shrinkage and complete remission observed in multiple treatment groups."

Preclinical • Ovarian Cancer

Antengene to Present Results from Three Programs at the 2024 SITC Annual Meeting (PRNewswire) - "Antengene Corporation Limited...announced that it will present three programs at the 2024 Society of Immunology in Cancer Annual Meeting (SITC 2024) to be held in Houston from November 6-10, 2024."

Preclinical • Acute Myelogenous Leukemia